Global S&T Development Trend Analysis Platform of Resources and Environment
UKRI invests £13 m in life saving projects to improve diagnosis and treatment | |
admin | |
2020-07-03 | |
发布年 | 2020 |
语种 | 英语 |
国家 | 英国 |
领域 | 气候变化 |
正文(英文) | 03/07/2020 ![]() Six projects that combine data from blood tests, tissue analysis, imaging techniques, genetic profiles and medical history, will share a £13 million grant from UKRI’s industrial strategy challenge fund. They are the winners of a competition run by Innovate UK on behalf of UK Research and Innovation (UKRI) and form part of the government’s commitment to increase research and development investment to 2.4% of GDP by 2027. The projects, which focus on cancer, liver and bowel health, will use AI to bring together and better interpret data from multiple sources, leading to improved diagnoses, more precise treatments and fewer deaths and other health problems among affected people. They involve partners across the UK, including Northern Ireland and Scotland. The projects will combine genomic, tissue analysis and other data, so that we can detect and diagnose disease more accurately and earlier and develop more precise treatments for a number of serious conditions that blight the lives of millions of people across the UK. They bring together the different strengths of academia, charities, digital health and diagnostics companies and include both small businesses and bigger companies, like Roche, to attract nearly £16 million of private sector funding. UKRI is also partnering with Cancer Research UK, which is contributing up to £3 million to the cancer-focused projects. The projects are:
More information
The INCISE project - INtegrated TeChnologies for Improved Polyp SurveillanacE – is a collaboration between University of Glasgow, NHS Greater Glasgow and Clyde, and Industry (Canon, BioClavis, OracleBio), which aims to deliver a tool to more accurately predict which patients with pre-cancerous growths in their bowels, called polyps, will develop further polyps. For all enquiries, please contact cancersci-incise@glasgow.ac.uk DART (The Integration and Analysis of Data Using Artificial Intelligence to Improve Patient Outcomes with Thoracic Diseases), led by the University of Oxford, will accelerate lung cancer diagnosis, increasing the likelihood that treatment will be successful. Academics, NHS clinicians, the Roy Castle Lung Cancer Foundation and industrial partners (Roche Diagnostics, GE Healthcare, Optellum) will work with the NHS England Lung Health Checks programme to combine clinical, imaging and molecular data for the first time using artificial intelligence algorithms. They aim to more accurately and quickly diagnose and characterise lung cancer with fewer invasive clinical procedures to improve patient outcomes. ID LIVER is a new consortium, led by The University of Manchester (UoM) and Manchester University NHS Foundation Trust (MFT), which has been awarded £2.5 million from the UK Government’s Innovate UK Industrial Strategy Challenge Fund to help patients with liver disease receive earlier, more accurate, and potentially life-saving diagnoses. For more information contact Kate Banks, Communications Manager, Manchester University NHS Foundation Trust: kate.banks@mft.nhs.uk on 0161 701 0260 / 07873 205 676 or Mike Addelman, Media Relations Officer, Faculty of Biology, Medicine and Health, University of Manchester: Michael.Addelman@manchester.ac.uk or 0161 275 2111, 07717 881567. Project DELTA aims to improve the diagnosis of oesophageal cancer. It is a collaboration between the Universities of Cambridge, Oxford, Kings College London, the PHG Foundation and Cyted. Advisory Board support is provided by Action Against Heartburn, Heartburn Cancer UK, the West Yorkshire and Harrogate Cancer Alliance and Newcastle University. We will develop algorithms to identify individuals most at risk. These people will be offered a Cytosponge™-TFF3 test, which can be delivered in an office setting. Cyted will develop AI algorithms to assist pathologists with rapid diagnoses. People diagnosed with Barrett’s oesophagus can then be monitored regularly for early signs of cancer. Contact: office@deltaproject.org Motilent’s mission is to change the way we see the gut quite literally by developing tools to improve our understanding of digestive disease. This UKRI project will specifically develop technology to increase the speed and accuracy of routine testing in Crohn’s Disease helping to get patients on the right medication at the right time to minimise intestinal inflammation. Working with Great Ormond Street (GOSH), University College London and University of Nottingham we will develop technology that truly meets patient and practitioner needs and maximises value for the NHS in the treatment of this chronic and expensive disease. Find out more at info@motilent.co.uk or visit motilent.co.uk ACTIONED (integrAted moleCular soluTIons fOr diagNostics and Early Detection), a project led by Queen’s University Belfast, aims to improve early detection of relapse in patients with early stage colorectal cancer by integrating genomics data from blood and tumour samples with digital pathology data using deep-learning algorithms. Working in partnership with Roche Diagnostics and Sonrai Analytics, ACTIONED’s vision is to develop a novel approach to identify patients that can be spared toxicity from chemotherapy as well as those that will benefit from more intensive or targeted treatments. For more information contact Zara McBrearty Z.McBrearty@qub.ac.uk Please sign up to our weekly newsletter to keep up to date: Share: |
URL | 查看原文 |
来源平台 | UK Research and Innovation |
文献类型 | 新闻 |
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/280796 |
专题 | 气候变化 |
推荐引用方式 GB/T 7714 | admin. UKRI invests £13 m in life saving projects to improve diagnosis and treatment. 2020. |
条目包含的文件 | 条目无相关文件。 |
个性服务 |
推荐该条目 |
保存到收藏夹 |
查看访问统计 |
导出为Endnote文件 |
谷歌学术 |
谷歌学术中相似的文章 |
[admin]的文章 |
百度学术 |
百度学术中相似的文章 |
[admin]的文章 |
必应学术 |
必应学术中相似的文章 |
[admin]的文章 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论